Up-regulation of endothelial nitric oxide synthase expression by cyclic guanosine 3′,5′-monophosphate  by Ravichandran, Lingamanaidu V. & Johns, Roger A.
FEBS 16205 FEBS Letters 374 (1995) 295 298 
Up-regulation of endothelial nitric oxide synthase xpression by 
cyclic guanosine 3',5'-monophosphate 
Lingamanaidu V. Ravichandran, Roger A. Johns* 
Department of Anesthesiology, Box 238, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA 
Received 28 July 1995 
Abstract In this study, the role of cyclic GMP, the end product 
of the NO-cyclic GMP signalling pathway, in the regulation of 
ecNOS was investigated. Bovine pulmonary endothelial cells 
were exposed to 8-bromo-cyclic GMP and its effect on NO pro- 
duction, ecNOS protein, and mRNA levels was analyzed. Endo- 
thelial cells on exposure to 8-bromo-cyclic GMP produced signif- 
icantly increased amounts of NO, detected as increased cyclic 
GMP in cocultures with vascular smooth muscle cells both under 
basal conditions and with agonist stimulation. 8-Bromo-cyclic 
GMP significantly increased the ecNOS protein and mRNA lev- 
els as detected on Western and Northern blots respectively. This 
8-bromo-cyclic GMP mediated increase of NO production, 
ecNOS protein and mRNA levels suggests that cyclic GMP 
up-regulates the expression of ecNOS. Thus, there may be an 
intercellular feedback mechanism involved at the molecular level 
in the expression of the NO-cyclic GMP signalling pathway in 
blood vessels. 
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1. Introduction 
In the vasculature, nitric oxide (NO) produced in the endo- 
thelial cells by the constitutive isoform of NO synthase (ecNOS) 
acts as an important signal transduction system for the activa- 
tion of soluble guanylate cyclase and subsequent cyclic GMP 
production in the vascular smooth muscle (VSM) [1,2]. This 
cyclic GMP, in a cascade of reactions, produces vascular elax- 
ation [1,3]. NO thereby acts as a potent vasodilator and regula- 
tor of vascular tone and controls basal blood pressure [1-3]. In 
the vasculature, in addition to its potent vasodilator effects, NO 
has also been implicated in a wide variety of physiologic events 
such as modulation of platelet aggregation and adhesion, inhi- 
bition of smooth muscle proliferation and endothelin genera- 
tion [1 5]. In addition, endothelial NO production is impaired 
in many types of vascular diseases including atherosclerosis and 
hypertension [3,5]. 
The ecNOS is activated and NO release is stimulated by 
receptor mediated agonists such as acetylcholine, bradykinin, 
substance P, histamine and receptor independent calcium ino- 
phores such as A23187 and also by fluid shear stress [6,7]. In 
addition, it has been shown that certain factors influence the 
expression of the ecNOS mRNA.  Tumor necrosis factor-~ [8], 
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shear stress [7,9], chronic exercise training [10], protein kinase 
C [11] and lysophosphatidylcholine [12] were reported to regu- 
late the molecular expression of ecNOS. Thus, there is now 
sufficient evidence to suggest hat the expression of ecNOS, 
though it is a constitutive isoform, is subject to regulation by 
a variety of stimuli. 
Recently the ability of cyclic GMP to alter specific gene 
expression including the regulation of early gene expression 
such as c-fos and junB has been reported [13,14]. On the basis 
of these considerations, we examined the possibility that cyclic 
GMP, the end product of NO-cyclic GMP signalling pathway, 
may modulate the expression and/or the activity of ecNOS as 
a potential mechanism of feedback regulation of this intercellu- 
lar signalling pathway. 
2. Materials and methods 
2.1. Chemicals" 
8-Bromo guanosine 3',5'-cyclic monophosphate (8-bromo-cyclic 
GMP), L-arginine, NADPH, calmodulin, pepstatin A, EDTA, EGTA, 
leupeptin, ATP and bradykinin were obtained from Sigma Chemical 
Co. Bio-Rad protein assay reagent was obtained from Bio-Rad Labo- 
ratories. Medium 199, streptomycin, penicillin, thymidine and Dul- 
becco's phosphate-buffered saline (PBS) were obtained from Gibco 
BRL. Fetal bovine serum was from Hyclone Laboratories. Anti ecNOS 
mouse IgG~ monoclonal antibody was obtained from Transduction 
Laboratories. 4091 bp EcoR1 ecNOS cDNA fragment is a kind gift 
from William Sessa [15]. 780 pb XbaI-PstI glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) cDNA fragment is from American Type 
Culture Collection. All other chemicals used were of analytical grade. 
2.2. Endothelial and VSM cell culture 
Bovine pulmonary endothelial and VSM cells were isolated and 
maintained as described before [16,17]. Briefly, a pure culture of endo- 
thelial cells was obtained by fluorescent-activated c ll sorting using 
acetylated low density lipoprotein as the fluorescent marker. Endothe- 
lial cultures were then further identified by: (1) typical cobblestone 
morphology, (2) antibody staining for factor VIII antigen, and 
(3) demonstrating byNorthern blot a single messenger RNA for endo- 
thelial cell fl-actin and, on immunocytochemistry, he absence of im- 
munostaining for c~-actin. The VSM cells were identified by immunocy- 
tochemistry for smooth muscle c~-actin using a monoclonal antibody. 
For Western and Northern blotting studies, pulmonary endothelial 
cells grown in roller bottles in medium 199 supplemented with fetal calf 
serum (10%), thymidine (2.4 ,ug/ml), penicillin (100 U/ml) and strepto- 
mycin (100 pg/ml) were used. For co-culture studies, endothelial cells 
were placed in microcarrier culture by seeding 2x 10 v cells on 0.6 g of 
Cytodex 3 microcarrier beads (Pharmacia, Uppsala, Sweden) (4600 cm 2 
surface area/g) in 200 ml medium 199 containing fetal calf serum (20%), 
thymidine (2.4 pg/ml), penicillin (100 U/ml) and streptomycin (100 
pg/ml) and maintained in 2 liter roller bottles. The VSM cells were 
grown in 24-well plates in medium 199 supplemented with fetal calf 
serum (10%), penicillin (100 U/ml) and streptomycin (100 ¢tg/ml) and 
were used 3-5 days post-confluency. 
2.3. Co-culture of endothelial nd VSM cells 
Co-culture studies were performed as published [16]. Briefly, conflu- 
ent bovine pulmonary endothelial cells grown on the surface of the 
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microcarrier beads were exposed to 8-bromo-cyclic GMP (100/,tM), a 
lipophilic and a non-phosphodiesterase hydrolyzable cyclic GMP ana- 
log for 48 h in medium 199 supplemented with fetal calf serum (10%), 
penicillin (100 U/ml) and streptomycin (100/zg/ml). The coculture x- 
periments were initiated by plating the microcarrier beads containing 
the equivalent of 5 x 107 endothelial cells on to the VSM cells grown 
after epeated washing with PBS to remove the residual 8-bromo-cyclic 
GMR Bradykinin (1/IM) and ATP (100/zM) were used for stimulating 
ecNOS activity and endothelial NO release. The NO-dependent in- 
crease in cyclic GMP accumulation i  the VSM cells was measured as 
an assay of ecNOS activity and NO production in the endothelium. 
Also, to rule out the cross over of 8-bromo-cyclic GMP with the cyclic 
GMP assay, endothelial cells on microcarriers that were exposed to 
8-bromo-cyclic GMP were plated alone in 24-well plates at the same 
density as was done for cocultures and the residual cyclic GMP levels 
were measured and were used to rule out any cross over effect of 
8-bromo-cyclic GMP. Further, we checked the soluble guanylate 
cyclase mediated production of cyclic GMP in the endothelial cells alter 
stimulation with sodium nitroprusside (SNP; 10 ¢tM). SNP failed to 
increase the cyclic GMP production i  the pulmonary endothelial cells 
(n = 4, data not shown) that were used in the current experiments and 
these results are consistent with the early observation from our labora- 
tory that pulmonary endothelial cells lacked the soluble guanylate 
cyclase [17]. 
2.4. Cyclic GMP assays 
Cyclic GMP was extracted in 0.1 N HCI (0.5 ml) and measured by 
automated radioimmunoassay of acetylated HCI extracts according to 
the methods of Harper and Brooker [18], as modified by Patel and 
Linden [19]. 
2.5. Preparation of ecNOS from eultured endothelial cells 
The membrane bound ecNOS was solubilized as previously described 
[20,21] with slight modifications. Briefly, the bovine pulmonary endo- 
thelial cells that were exposed to 8-bromo-cyclic GMP or the vehicle 
for 48 h were scraped and washed in PBS and then suspended and 
homogenized in ice-cold 50 mM Tris.HCl (pH 7.4), containing 0.1 mM 
EDTA, 0.1 mM EGTA, 0.1% 2-mercaptoethanol, 1 mM phenylmeth- 
ylsulfonyl fluoride, 2 ktM leupeptin and 1/~M pepstatin A. The homo- 
genate was centrifuged at100,000 x g for 60 min at 4°C. The particulate 
fraction was then solubilized with the detergent 3-[(3-cholami- 
dopropyl)dimethylammonio]- 1 -propanesulfonate (CHAPS; 20 m M) in 
homogenizing buffer containing 10% glycerol and protease inhibitors. 
2.6. Western blotting 
The particulate fractions that were collected, as described above were 
then analyzed by electrophoresis on a 7% SDS polyacrylamide g l, and 
then transferred electrophoretically to nitrocellulose paper to give a 
Western blot. The blot was blocked for non-specific binding with 1% 
BSA and 0.1% Tween at room temperature for 1 h. After blocking, the 
blot was washed with Tris-HCl buffered saline (pH 7.4), then incubated 
with the primary mouse anti-ecNOS antibody for 2 h and washed. The 
blot was then incubated with a secondary antibody, a peroxidase- 
conjugated goat anti-mouse IgG, which detects the primary antibody. 
After washing, the blot was incubated in ECL (Amersham), a chemilu- 
minescent substrate for horseradish peroxidase. The luminescence was 
detected by exposure of the blot to X-ray film and quantitated using 
a densitometer. 
2. 7. Northern blotting 
For mRNA analysis by Northern blotting of poly(A) ÷ RNA, total 
RNA was isolated by the method of Chomczynski [22] after lysing the 
cells with Tri reagent (Molecular Research Center Inc.). Poly(A) + RNA 
was then purified from the total RNA using an oligo(dT)-cellulose 
affinity spin column and following the manufacturers instructions (5 
Prime-3 Prime Inc.). Northern blot analysis of 24  ktg poly(A) + RNA 
was performed by following the standard procedure as described by 
Sambrook et al. [23]. After random primed labeling, the [0~-32p]dCTP 
labeled cDNA probes for bovine ecNOS and GAPDH were then used 
for the hybridization ofthe blots overnight at 65°C. The blots were then 
washed twice in 2 x standard saline citrate (SSC)/0.1% sodium dodecyl 
sulfate (SDS) for 15 min at room temperature and then twice in 
0.4 x SSC/0.1% SDS for 15 min at 65°C, rinsed in 0.1 M phosphate 
buffer, pH 7.5, dried and the blots with the hybridized probes were 
detected by autoradiography and quantitated using a phosphorimager 
and IMAGEQUANT software (Molecular Dynamics). 
3. Results 
Bioassay experiments were performed using endothelial and 
VSM cell coculture where the production of cyclic GMP by the 
VSM cells was taken as a measure of NO production by the 
cocultured endothelial cells. When the VSM cells were cocul- 
tured with 8-bromo-cyclic GMP treated endothelial cells, sig- 
nificantly increased cyclic GMP levels (*P < 0.05 level, n -- 4 
and representative of three independent experiments) were ob- 
served, both under basal and agonist (bradykinin and ATP) 
stimulated conditions as compared to the respective controls 
(Fig. 1 ). This observed increase in cyclic GMP levels reflects the 
actual production of endothelial NO-dependent cyclic GMP 
since cross over of 8-bromo-cyclic GMP present in the endothe- 
lial cells with the cyclic GMP assay has been ruled out as 
described in section 2. Under basal conditions, the production 
of cyclic GMP by the VSM cells was about 2.8-fold higher 
(from 35.49 + 9.25 to 137.65 + 15.89 pmol cyclic GMP/well) 
with the endothelial cells that were exposed to 8-bromo-cyclic 
GMP, as compared to the controls. Similarly, bradykinin 
and ATP stimulated NO production, and hence cyclic GMP 
formation, were increased by ~40% (from 129.61 _+ 6.56 
to 182.33 + 3.76 pmol cyclic GMP/well) and 70% (from 
138.53 + 7.33 to 240.02 + 18.19 pmol/well) with 8-bromo-cyclic 
GMP treated endothelial cells as compared to the respective 
controls. 
On the Western blot, using a mouse monoclonal antibody 
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Fig. 1. Effect of 8-bromo-cyclic GMP on endothelial NO production 
as assessed by the levels of cyclic GMP produced in endothelial nd 
VSM cell cocultures. After exposure to 8-bromo-cyclic GMP (100,uM) 
for 48 h, the endothelial cells grown on the surface of the microcarrier 
beads were repeatedly washed with PBS and were plated on to the VSM 
cells. The NO mediated cyclic GMP production was measured under 
basal and agonist (bradykinin and ATP) stimulated conditions. Values 
are mean + S.E.M. of four determinations and representative of three 
independent experiments. The values represent the actual endothelial 
NO-dependent increase in cyclic GMP after ruling out the cross over 
of 8-bromo-cyclic GMP with the cyclic GMP assay as described in 
section 2. USignificantly different from baseline (P < 0.05). *Signifi- 
cantly different from corresponding control (P < 0.05). 
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Fig. 2. Western blot demonstrating the effect of 8-bromo-cyclic GMP 
on ecNOS protein levels in endothelial cells. After exposure to 8-bromo 
cyclic GMP (100#M) for 48 h, the particulate fractions of the endothe- 
lial cells were separated and Western blotting was performed with 40 
,ug protein as described in section 2 and probed for ecNOS using a 
monoclonal antibody specific to ecNOS. Lane 1 = molecular weight 
standards; lanes 2 ~, = protein from control endothelial cells; and lanes 
5-7 = protein from 8-bromo-cyclic GMP exposed endothelial cells. 
specific to ecNOS, significantly increased ecNOS protein levels 
(*P < 0.05 level) were detected in the particulate fractions of 
8-bromo-cyclic GMP treated endothelial cells as compared to 
untreated controls (Fig. 2). The ecNOS protein levels were 
increased by 368 + 52% (n -- 8 from three independent experi- 
ments) on exposure to 8-bromo-cyclic GMP as compared to the 
control protein levels. 
The Northern blot results howed that 8-bromo-cyclic GMP 
treatment increased the level of ecNOS mRNA (Fig. 3). After 
normalizing for loading with the housekeeping gene GAPDH 
mRNA,  the ecNOS mRNA levels of the 8-bromo-cyclic GMP 
exposed endothelial cells were found to be significantly en- 
hanced (54 + 16%) as compared to the control ecNOS mRNA 
(*P < 0.05 level, n = 5 from three independent experiments). 
4. Discussion 
The present study demonstrates that cyclic GMP up-regu- 
lates the expression of ecNOS based on the following evidence. 
(1) Cyclic GMP production increased in endothelial nd VSM 
cell co-cultures when endothelial cells were pretreated with 
8-bromo cyclic GMR (2) EcNOS protein levels increased after 
endothelial cells were exposed to 8-bromo-cyclic GMP as ob- 
served on Western blot using an antibody specific to ecNOS. 
(3) Steady state levels of ecNOS mRNA increased in response 
to 8-bromo-cyclic GME 
8-Bromo cyclic GMP, in the current study, consistently 
caused an increase in the steady state levels of ecNOS mRNA. 
Under the current hybridization and washing conditions, we 
and others [15] have shown that the ecNOS cDNA probes do 
not cross-react with inducible NOS or brain NOS. Also, since 
the size of the brain NOS (about 10.4 kb) is more than twice 
the size of ecNOS (about 4.8 kb) and there exists a large differ- 
ence between the ecNOS and cytokine-inducible forms of NOS 
(only 50% amino acid homology), the increased steady state 
levels of mRNA observed in the present study, in response to 
8-bromo-cyclic GMP, reflects an up-regulation of the ecNOS 
gene. Thus the increased ecNOS protein levels in response to 
8-bromo-cyclic GMP and the increased cyclic GMP production 
in co-cultures of VSM cells and 8-bromo-cyclic GMP treated 
endothelial cells are consistent with the increase of ecNOS 
mRNA and support he hypothesis that 8-bromo-cyclic GMP 
up-regulates cNOS gene expression. 
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The expression of ecNOS, although it is a constitutive en- 
zyme, is subject o regulation by a variety of factors. In human 
umbilical vein endothelial cells (HUVEC), tumor necrosis fac- 
tor-c~ was shown to decrease the ecNOS mRNA levels in a 
dose-dependent manner by acting at the posttranscriptional 
level, thereby decreasing its half-life [8]. There are in vitro data 
showing that prolonged mechanical deformation of the endo- 
thelium by defined shear or cyclic stretching increases ecNOS 
gene expression, protein and activity [9,24]. In dogs, chronic 
exercise training was reported to increase cNOS mRNA and 
coronary vascular NO production [10]. Inhibition of protein 
kinase C by staurosporine or chelerythrine was shown to en- 
hance the levels of ecNOS mRNA, NO synthase protein and 
activity [11]. In HUVECs it was reported that lysophosphati- 
dylcholine increased the ecNOS mRNA levels by increasing its 
rate of synthesis and this was followed by increased ecNOS 
protein levels and activity [12]. 
Recently cyclic GMP has been implicated in regulating the 
expression of several proteins. Cyclic GMP was shown to 
down-regulate the atrial natriuretic peptide clearance receptors 
on cultured vascular endothelial cells [25]. In the HepG2 cell 
line, the human asialoglycoprotein receptor was shown to be 
posttranscriptionally regulated by cyclic GMP [26]. Rp-8- 
bromo cyclic GMPs (a cyclic GMP dependent protein kinase 
inhibitor) was reported to produce a dose-dependent decrease 
in erythropoietin mRNA levels in Hep3B cells in response to 
hypoxia [27]. The expression of cellular immediate early genes 
c-Jos and junB, was shown to increase in response to cyclic 
GMP in pheochromocytoma PC 12 cells [13]. Similarly, in tran- 
sient and stable transfection experiments involving mammalian 
cells, it was shown that cyclic GMP analogs activated phorbol 
ester response lement (TRE)-regulated promoters, increased 
DNA binding of AP-I and increased c-los and junB expression 
[14]. In hematopoietic cells, NO releasing agents and cyclic 
GMP analogs were reported to change the expression of differ- 
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Fig. 3. Northern blot analysis of the effect of 8-bromo-cyclic GMP on 
ecNOS mRNA levels in endothelial cells. After exposure of endothelial 
cells to 8-bromo-cyclic GMP (100#M) for 48 h, the poly(A) + RNA were 
isolated and Northern blotting was performed with 24 ktg mRNA as 
described in section 2 and probed for ecNOS and GAPDH using 
cDNA's specific tbr ecNOS and GAPDH. Lanes 1 and 2 = control 
mRNA; lanes 3 and 4 = mRNA from 8-bromo-cyclic GMP exposed 
endothelial cells. 
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entiation-associated genes and induce cellular differentiation 
[28]. Most recently, it was reported that cyclic GMP up-regu- 
lated inducible NO synthase xpression in VSM cells [29]. 
The current observation of up-regulation of ecNOS by 8- 
bromo-cyclic GMP indicate that cyclic GMP is involved in the 
regulation of the signalling pathway in which it can be pro- 
duced suggesting an intercellular feedback mechanism. To our 
knowledge, this is the first report about the regulation of 
ecNOS expression by cyclic GMP. This cyclic GMP mediated 
increase in the expression of ecNOS may play an important role 
in various pathophysiological conditions where elevated cyclic 
GMP levels were observed. 
Increased levels of cyclic GMP in the circulation and other 
body fluids has been reported in various clinical conditions. 
Plasma cyclic GMP levels are reported relatively sensitive to 
changes in clinical status with treatment of heart failure [30]. 
Elevated plasma cyclic GMP levels were reported in end-stage 
renal failure patients on chronic hemodialysis [31] and in cir- 
rhotic patients [32]. Plasma and urinary cyclic GMP has been 
reported to be elevated in patients with schizophrenia [33] and 
in certain malignancies such as ovarian cancer [34]. However, 
the physiological significance of these findings remains to be 
elucidated. Under such pathophysiologic conditions the in- 
creased cyclic GMP levels may influence the expression of 
ecNOS and the NO-cyclic GMP signalling pathway. 
A great deal of interest has focused on the role of endothe- 
lium derived factors in modulating smooth muscle cell function. 
It is now well established that the endothelium produces a 
variety of autacoids, including NO and endothelin, which influ- 
ence vascular smooth muscle reactivity and growth. The results 
of the present study showing that cyclic GMP can modify the 
expression of ecNOS, suggest hat the cells of the vascular 
media can in-turn alter the functions of the endothelium. 
Our current observations suggest hat cyclic GMP modu- 
lates, in part, ecNOS gene expression. It is possible that changes 
in the biological activity of soluble or particulate guanylate 
cyclases and cyclic GMP production under certain pathophys- 
iological conditions are likely to regulate cNOS and NO re- 
sponses. Currently, the mechanisms or the significance behind 
these events are not clear. Recently, the presence of AP-l sites 
have been reported in both the human [35] and bovine ecNOS 
promoter [36]. Also, cyclic GMP has been implicated in the 
induction of the immediate arly genes c-fos and junB and the 
formation of AP-1 complex [13,14]. Hence, one likely possibil- 
ity is that cyclic GMP might modulate the transcription of 
ecNOS gene through the increased formation and binding of 
AP-1 complex to the specific DNA sequence in ecNOS pro- 
moter. Currently, further studies are underway to define the 
mechanisms involved in this intercellular molecular egulation 
of ecNOS. 
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